Meloxicam mitigated methylglyoxal-induced glycative stress in rats

Document Type : Original Article

Authors

1 Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Ziauddin University, Karachi-75600, Pakistan

2 Department of Molecular Medicine, Ziauddin University, Karachi-75600, Pakistan

3 Department of Pharmacology, Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi, Pakistan

4 H.E.J. Research Institute of Chemistry, International Center for Chemical & Biological Sciences, University of Karachi, Karachi-75270, Pakistan

Abstract

Objective(s): Glycation is one of the primary underlying processes attributed to senescence and related diseases. No medicine currently targets this harmful manifestation. Drug repurposing is an efficient and cost-effective way of developing drugs. The present study evaluated meloxicam, a clinically used NSAID, for its ability to offer protection against glycative stress.
Materials and Methods: Methylglyoxal (MGO; 17.25 mg/kg) was administered for two weeks to create a rat model of glycative stress. Aminoguanidine (AG; 50 mg/kg) and Meloxicam (MEL; 0.15, 0.3, and 0.6 mg/kg) were used as standard and test agents, respectively. Afterward, the cognitive (Morris Water Maze), liver (LFT), and kidney (Creatinine) functioning were evaluated. The expression of genes of interest (TNF-α, RAGE, BACE, Glyoxalase, and VEGF) were estimated (qPCR) in the liver, brain, and kidney along with histopathology (H&E staining). Carboxymethyllysine (CML) levels in rat plasma were evaluated via ELISA.
Results: MEL treatment has significantly (P<0.05) protected the MGO-induced cognitive (duration in target quadrant, time taken to get to target quadrant, and the frequency of crossings via platform location), hepatic, and renal impairment. The qPCR data revealed that MEL prevented MGO-induced enhancement in the expression of genes of interest. Additionally, the CML levels were significantly (P<0.005) normalized by concomitant administration of MEL. Histopathological examination did not reveal any remarkable outcomes.
Conclusion: MEL has significantly mitigated the rats’ MGO-induced cognitive, liver, and kidney impairments. Hence, it appears to be a potential molecule for repurposing as an antiglycation agent.

Keywords

Main Subjects

References

1. Li Z, Zhang Z, Ren Y, Wang Y, Fang J, Yue H, et al. Aging and age‐related diseases: From mechanisms to therapeutic strategies. Biogerontology 2021; 22: 165-187.
2. Anguizola J, Matsuda R, Barnaby OS, Hoy K, Wa C, DeBolt E, et al. Glycation of human serum albumin. Clin Chim Acta 2013; 425: 64-76.
3. Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, et al. The role of advanced glycation end products in aging and metabolic diseases: Bridging association and causality. Cell Metab 2018; 28: 337-352.
4. Biedrzycki G, Wolszczak-Biedrzycka B, Dorf J, Michalak D, Żendzian-Piotrowska M, Zalewska A, et al. Antioxidant and anti-glycation potential of H2 receptor antagonists—in vitro studies and a systematic literature review. Pharmaceuticals 2023; 16: 1273-1292.
5. Lotan R, Ganmore I, Shelly S, Zacharia M, Uribarri J, Beisswenger P, et al. Long term dietary restriction of advanced glycation end-products (AGEs) in older adults with type 2 diabetes is feasible and efficacious-results from a pilot RCT. Nutrients 2020; 12: 3143-3156.
6. Rungratanawanich W, Qu Y, Wang X, Essa MM, Song B-J. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med 2021; 53: 168-188.
7. Damrath JG, Creecy A, Wallace JM, Moe SM. The impact of advanced glycation end products on bone properties in chronic kidney disease. Curr Opin Nephrol 2021; 30: 411-417.
8. Pereira RM, Botezelli JD, da Cruz Rodrigues KC, Mekary RA, Cintra DE, Pauli JR, et al. Fructose consumption in the development of obesity and the effects of different protocols of physical exercise on the hepatic metabolism. Nutrients 2017; 9: 405-426.
9. Jakubczyk K, Dec K, Kałduńska J, Kawczuga D, Kochman J, Janda K. Reactive oxygen species-sources, functions, oxidative damage. Pol Merkur Lekarski 2020;48:124-127.
10. Schalkwijk C, Stehouwer C. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. Physiol Rev 2020; 100: 407-461.
11. Nigro C, Leone A, Fiory F, Prevenzano I, Nicolò A, Mirra P, et al. Dicarbonyl stress at the crossroads of healthy and unhealthy aging. Cells 2019; 8: 749-776.
12. Khan MI, Ashfaq F, Alsayegh AA, Hamouda A, Khatoon F, Altamimi TN, et al. Advanced glycation end product signaling and metabolic complications: Dietary approach. World J Diabetes 2023; 14: 995-1014.
13. Khan M, Gothawal R. Advanced glycation endproducts,(ages): Formation, complication and pharmacological evaluation to its inhibition. Asian J Res Med Pharm Sci 2018; 3: 1-18.
14. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18: 41-58.
15. Younus H, Anwar S. Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complication. Int J Health Sci 2016;10: 261-278.
16. Perrone A, Giovino A, Benny J, Martinelli F. Advanced glycation end products (AGEs): Biochemistry, signaling, analytical methods, and epigenetic effects. Oxid Med Cell Longev 2020; 2020: 3818196-3818214.
17. Barnette DA, Schleiff MA, Datta A, Flynn N, Swamidass SJ, Miller GP. Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam. Toxicol Lett 2021; 338: 10-20.
18. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti‐inflammatory drugs and beyond. IUBMB Life 2014; 66: 803-811.
19. Khalil NY, Aldosari KF. Profiles of Drug Substances, Excipients and Related Methodology. 45: Elsevier; 2020. p. 159-197.
20. Ahmed H, Fayyaz TB, Khatian N, Usman S, Khurshid Y, Sikandar B, et al. Phloroglucinol ameliorated methylglyoxal induced harmful effects in rats. Naunyn Schmiedebergs Arch Pharmacol 2024; 397: 9023-9032.
21. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci methods 1984; 11: 47-60.
22. Khan RA, Mirza T, Fayyaz TB. The effects of Ficus carica on male and female reproductive capabilities in rats. Evid Based Complement Alternat Med 2022; 2022: 1799431-1799443.
23.    Jiang K, Huang C, Jiao R, Bai W, Zheng J, Ou S. Adducts formed during protein digestion decreased the toxicity of five carbonyl compounds against Caco-2 cells. J Hazard Mater 2019; 363: 26-33.
24. Jung E, Kang WS, Jo K, Kim J. Ethyl pyruvate prevents renal damage induced by methylglyoxal‐derived advanced glycation end products. J Diabetes Res 2019; 2019: 4058280-4058289.
25. Othman MZ, Hassan Z, Has ATC. Morris water maze: A versatile and pertinent tool for assessing spatial learning and memory. Exp Anim 2022; 71: 264-280.
26. Szczepanik J, Garcia A, Almeida G, Cunha M, Dafre A. Protective effects against memory impairment induced by methylglyoxal in mice cotreated with FPSZM1, an advanced glycation end products receptor antagonist. Acta Neurobiol Exp 2020; 80: 364-374.
27. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm Res 1995; 44: 423-433.
28. Pawlukianiec C, Gryciuk ME, Mil KM, Żendzian-Piotrowska M, Zalewska A, Maciejczyk M. A new insight into meloxicam: Assessment of antioxidant and anti-glycating activity in in vitro studies. Pharmaceuticals 2020; 13: 240-259.
29. Yang Y, He Q, Wang H, Hu X, Luo Y, Liang G, et al. The protection of meloxicam against chronic aluminum overload-induced liver injury in rats. Oncotarget 2017; 8: 23448-23458.
30. Moreira AP, Vizuete AFK, Zin LEF, de Marques CO, Pacheco RF, Leal MB, et al. The methylglyoxal/RAGE/NOX-2 pathway is persistently activated in the hippocampus of rats with STZ-induced sporadic Alzheimer’s disease. Neurotox Res 2022; 40: 395-409.
31. Ding L, Hou Y, Liu J, Wang X, Wang Z, Ding W, et al. Circulating concentrations of advanced glycation end products, carboxymethyl lysine and methylglyoxal are associated with renal function in individuals with diabetes. J Ren Nutr 2024; 34: 154-160.
32.    Hollenbach M. The role of glyoxalase-I (Glo-I), advanced glycation endproducts (AGEs), and their receptor (RAGE) in chronic liver disease and hepatocellular carcinoma (HCC). Int J Mol Sci 2017; 18: 2466-2487.
33. Toriumi K, Miyashita M, Suzuki K, Tabata K, Horiuchi Y, Ishida H, et al. Role of glyoxalase 1 in methylglyoxal detoxification–the broad player of psychiatric disorders. Redox Biol 2022; 49: 102222-102230.
34. Takeuchi M, Sakasai-Sakai A, Takata T, Takino J-i, Koriyama Y, Kikuchi C, et al. Intracellular toxic AGEs (TAGE) triggers numerous types of cell damage. Biomolecules 2021; 11: 387-406.
35. Nakano T, Kumiko T, Mizumasa T, Kuroki Y, Tsuruya K, Kitazono T. The glucose degradation product methylglyoxal induces immature angiogenesis in patients undergoing peritoneal dialysis. Biochem Biophys Res Commun 2020; 525: 767-772.
36. Li WY. Investigation on the Effect of Hyperglycemia-induced Methylglyoxal in Neurodegenerative Disorder: Hong Kong Baptist University. 2023; 12: 1-163.
37. Jung E, Park S-B, Jung WK, Kim HR, Kim J. Antiglycation activity of aucubin in vitro and in exogenous methylglyoxal injected rats. Molecules 2019; 24: 3653-3662.
38. Mirzayan M, Probst C, Samii M, Krettek C, Gharabaghi A, Pape H, et al. Histopathological features of the brain, liver, kidney and spleen following an innovative polytrauma model of the mouse. Exp Toxicol Pathol 2012; 64: 133-139.
39. Anwar L, Ali SA, Khan S, Uzairullah MM, Mustafa N, Ali UA, et al. Fenugreek seed ethanolic extract inhibited formation of advanced glycation end products via scavenging reactive carbonyl intermediates. Heliyon 2023; 9: e16866-e16873.
40. Lai SWT, Lopez Gonzalez EDJ, Zoukari T, Ki P, Shuck SC. Methylglyoxal and its adducts: Induction, repair, and association with disease. Chem Res Toxicol 2022; 35: 1720-1746.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 5
May 2025
Pages 647-654

Files

Share

How to cite

Statistics